Protara Therapeutics, Inc.
NASDAQ:TARABiotechnology
-$0.05 today
- Market cap
- $144.07M
- Beta
- 1.45
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$1.48
Volume 1.15M
Average 0.73M
TARA Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Protara Therapeutics, Inc.NASDAQ: TARA
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$11.68M, compared with -$87.23M a year earlier.
Context
- Net debt amounted to 6.1% of total assets at the end of Q1 FY2026, down 45.7 pp from a year earlier.
- Net debt grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net debt keeps rising in the next quarterly balance sheet after a +86.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (46.3M) USD
- Year-over-year change
- +70.8%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (46.3M) | +70.8% |
| FY2024 | 2024-12-31 | (158.32M) | -364.0% |
| FY2023 | 2023-12-31 | (34.12M) | -92.3% |
| FY2022 | 2022-12-31 | (17.74M) | +37.7% |
| FY2021 | 2021-12-31 | (28.49M) | — |
Net Debt vs competitors
How TARA compares with its peers on the latest reported figures
- TARA's Mar 2026 net debt of -$11.68M is the 7th highest of the 10 companies compared; the peer median is -$8.25M.
- Its year-over-year change of +86.6% is the 3rd highest of 10, against a peer median of -14.7%.
- Net debt amounts to 6.1% of total assets for TARA, versus a peer median of 13.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $35.91M | -12.8% | — | 27.8% | |
| Mar 2026 | $5.27M | +376.7% | — | 5.2% | |
| Mar 2026 | $207.45K | +103.8% | — | 6.2% | |
| Mar 2026 | -$4.04M | +81.9% | — | 3.4% | |
| Mar 2026 | -$8.25M | -2615.1% | — | 13.8% | |
| Mar 2026 | -$9.38M | -180.9% | — | 3.2% | |
| Mar 2026 | -$11.68M | +86.6% | — | 6.1% | |
| Mar 2026 | -$36.52M | -14.7% | — | 45.7% | |
| Sep 2026 | -$134.11M | -206.0% | — | 95.1% | |
| Mar 2026 | -$175.53M | -272.0% | — | 72.6% | |
| Peer median (excluding TARA) | -$8.25M | -14.7% | — | 13.8% | |
Competitors are the stored peer set for TARA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 35.72M | 24.13M | 39.59M | 162.8M | 49.66M |
| Short-term Investments | 55.51M | 60.24M | 25.99M | 7.49M | 105.9M |
| Net Receivables | 634K | 486K | 242K | 0 | 1.26M |
| Inventory | 0 | 1.16M | 0 | 0 | 0 |
| Other Current Assets | 34K | (1.04M) | 37K | 2K | 65K |
| Total Current Assets | 93.11M | 86.15M | 68.71M | 172.16M | 159.5M |
| Property, Plant & Equipment (Net) | 8.89M | 7.87M | 6.56M | 5.28M | 3.93M |
| Goodwill | 29.52M | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 84K | 2.66M | 3.25M | 2.93M |
| Long-term Investments | 39.47M | 17.89M | 0 | 0 | 42.34M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.61M | 1.31M | 1.03M | 772K | 765K |
| Total Non-current Assets | 79.48M | 27.14M | 10.25M | 9.3M | 49.96M |
| Total Assets | 172.6M | 113.29M | 78.95M | 181.45M | 209.47M |
| Account Payables | 954K | 1.59M | 2.43M | 4.43M | 3.47M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 41K | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.8M | 2.54M | 2.11M | 2.53M | 3.27M |
| Total Current Liabilities | 4.3M | 5.74M | 6.15M | 10.96M | 10.94M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 6.38M | 5.47M | 4.48M | 3.36M | 2.12M |
| Total Liabilities | 10.68M | 11.21M | 10.63M | 14.32M | 13.06M |
| Common Stock | 11K | 11K | 11K | 35K | 54K |
| Retained Earnings | (94.01M) | (159.96M) | (200.38M) | (244.98M) | (302.42M) |
| Accumulated OCI | (211K) | (688K) | (31K) | 2K | 90K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 161.91M | 102.08M | 68.32M | 167.13M | 196.41M |
| Total Debt | 7.24M | 6.38M | 5.47M | 4.48M | 3.36M |
| Net Debt | (28.49M) | (17.74M) | (34.12M) | (158.32M) | (46.3M) |
Protara Therapeutics, Inc.
NASDAQ:TARA
Intrinsic Alpha fair value
Locked
Current Price
$2.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.